正大企业国际(03839.HK)上半年股东应占溢利1700万美元

Group 1 - The company's revenue increased approximately twofold to $323.3 million for the six months ending June 30, 2025 [1] - The net profit attributable to shareholders for the first half of the year was $17 million, compared to $2 million in the first half of 2024 [1] - The significant profit increase was primarily driven by substantial growth in the company's biochemical business [1] Group 2 - The basic and diluted earnings per share were 6.7 cents, compared to 0.8 cents in the first half of 2024 [1] - The company's board decided not to declare an interim dividend, consistent with the first half of 2024 [1]